Edition:
United States

Pluristem Therapeutics Inc (PSTI.PH)

PSTI.PH on Philadelphia Stock Exchange

1.55USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$1.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
864
52-wk High
$1.86
52-wk Low
$0.76

Latest Key Developments (Source: Significant Developments)

Pluristem receives positive feedback from FDA, gears up for phase III trial of PLX-PAD in critical limb ischemia
Tuesday, 2 Aug 2016 07:30am EDT 

Pluristem Therapeutics Inc : Pluristem receives positive feedback from FDA and gears up for Phase III trial Of PLX-PAD in critical limb ischemia . Multinational study to be conducted in U.S. and Europe . Estimated trial enrollment of approximately 250 patients . Also moving CLI indication forward in Europe and Japan .Look forward to starting U.S. Phase III trial with our cell therapy for treatment of CLI by early 2017.  Full Article

Pluristem advances towards late-stage trial of PLX-PAD for recovery post hip surgery
Wednesday, 27 Jul 2016 07:00am EDT 

Pluristem: Pluristem advances towards multinational phase III trial of PLX-PAD to improve recovery following surgery for hip fracture . Has already submitted protocol to European medicines agency for a single pivotal study in this indication .Pluristem is planning to meet with FDA later this year to discuss phase iii protocol.  Full Article

Pluristem advances its U.S. FDA trial in hematologic indication
Monday, 11 Jul 2016 07:30am EDT 

Pluristem Therapeutics Inc : Pluristem advances its U.S. FDA trial in hematologic indication .Trial received clearance from U.S. Food and Drug Administration earlier this year and enrollment is planned to begin in coming months.  Full Article

Pluristem completes enrollment of 150 patients in phase II intermittent claudication trial
Monday, 16 May 2016 03:00am EDT 

Pluristem Therapeutics Inc : Data release on track for 2017 .Pluristem completes enrollment of 150 patients in phase ii intermittent claudication trial.  Full Article

U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem Therapeutics Inc's PLX-PAD Cells
Thursday, 31 Dec 2015 06:59am EST 

Pluristem Therapeutics Inc:Says that the U.S. Food and Drug Administration has granted the Company's PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia.Preeclampsia is among the most common medical complications of pregnancy and a leading cause of premature births, stillbirths and neonatal and maternal deaths.There is no cure except delivery.Due to high risks to the mother, women diagnosed with severe preeclampsia are usually delivered promptly, even if the baby will be born prematurely and may suffer permanent disabilities as a result.Severe preeclampsia occurs in approximately 1% of pregnancies in Western countries.  Full Article

Pluristem Therapeutics Inc expand cooperation agreement to include orthopedic indications
Monday, 12 Oct 2015 07:00am EDT 

Pluristem Therapeutics Inc:Says expanded its five-year Collaborative Research Agreement with Berlin-Brandenburg Center for Regenerative Therapy at Charité - University Medicine Berlin.Pluristem and Charité jointly completed successful orthopedic Phase I/II study using placental expanded cells in muscle injury.  Full Article

Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in Range of Indications
Monday, 17 Aug 2015 03:00am EDT 

Pluristem Therapeutics Inc:Says that the U.S. Patent and Trademark Office has issued to the Company patent # 9,096,827 titled Adherent Cells From Placenta Tissue and Use Thereof in Therapy.  Full Article

Pluristem Therapeutics to sell 6.8 mln shares, warrants to purchase up to 4.08 mln shares
Thursday, 25 Jun 2015 09:22am EDT 

Pluristem Therapeutics Inc:Announces pricing of registered direct offering of common stock and warrants.To sell 6.8 mln shares, warrants to purchase up to 4.08 mln shares of common stock at combined price of $2.50 per share, related warrants.Gross proceeds from the offering are expected to be approximately $17.0 million.Maxim Group LLC acted as lead placement agent for the offering.Offering is expected to close on or around June 30.  Full Article

Pluristem Therapeutics Inc granted australian patent for 3D cell expansion technology & use of PLX Cells
Wednesday, 24 Jun 2015 03:16am EDT 

Pluristem Therapeutics Inc:Says that it has been granted an Australian patent titled Adherent Cells From Placenta Tissue and Use Thereof in Therapy.Patent # 2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions.Says these include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases.Patent term will extend until 2027.  Full Article

Pluristem gets European patent for use of cells to help treat damaged bone marrow
Wednesday, 6 May 2015 03:00am EDT 

Pluristem Therapeutics Inc:Says that it has been issued Patent No. EP2366775B1, titled 'Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy', by the European Patent Office.Says this patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem's methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.  Full Article

BRIEF-Pluristem says FDA has given positive feedback on proposed phase III trial

* Says as of June 30 had approximately $33 million in cash and cash equivalents, bank deposits, restricted deposits and marketable securities